RADIONUCLIDES IN MOLECULAR IMAGING & THERAPY FINAL PROGRAMME · of Medicine, Radiopharmacy, Physics...

34TH

INTERNATIONAL AUSTRIANWINTER SYMPOSIUM

22 – 25 January 2020Zell am See | Salzburg, Austria

RADIONUCLIDES IN MOLECULAR IMAGING & THERAPY

FINAL PROGRAMME

3

Thursday, 23.1.2020

2

INVITATIONOn behalf of the Austrian Society of Nuclear Medicine & Molecular Imaging (OGNMB) and the Congress Committee we have the pleasure of inviting you to Zell am See, located in the heart of Austria.

The symposium is organized by the Austrian Society of Nuclear Medicine & Molecular Imaging (OGNMB). The 2020 meeting will be held under the auspices of our Congress President, Prof. Ora Israel from Haifa/Israel.Renown clinical and preclinical experts from various domains of Medicine, Radiopharmacy, Physics and experimental Nuclear Medicine are expected to join us for this International Symposium. Invited lectures will cover a broad range of topics in scientific, diagnostic and therapeutic applications of Nuclear Medicine, and be accompanied by free submissions from experts in the field. We would like to invite you to hear and discuss exciting interdisciplinary presentations as well as informative CME sessions and to meet with friends in an picturesque environment that stimulates your thoughts and creativity.

We look forward to welcoming you in Zell am See.

Welcome

Marcus Hacker, Vienna

President OGNMB

Ora Israel, Haifa

Scientific Chair

Alexander Becherer, Feldkirch

Congress Chair

CONGRESS ORGANISATION

Faculty

• Alexander Becherer, Feldkirch• Marcus Hacker, Vienna• Ora Israel, Haifa• Amir Kurtaran, Vienna• Markus Mitterhauser, Vienna• Armin Stegmayr, Innsbruck• Tatjana Traub-Weidinger, Vienna

GENERAL INFORMATION

Congress VenueFerry Porsche CONGRESS CENTERBrucker Bundesstraße 1a A - 5700 Zell am See +43 6542 474 75 0 +43 6542 474 75 75email: [email protected] URL: www.fpcc.at

Congress Organisation OGNMB HeadquarterSchmalzhofgasse 26 A – 1060 Vienna +43 1 890 44 27 +43 1 890 44 29 email: [email protected] URL: www.ognmb.at

WLANUser: OGNMBPassword: OGNMB2020

Congress LanguageEnglish

Congress Office

Wednesday 22 January 2020 09:00 – 19:00

Thursday 23 January 2020 07:30 – 18:00

Friday 24 January 2020 07:30 – 18:00

Saturday 25 January 2020 07:30 – 12:00

14 European CME Credits

The ‘Radionuclides in Molecular Imaging and Therapy - 34th International Austrian Winter Symposium”, January 22 – 25, 2020 is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The event ‘Radionuclides in Molecular Imaging and Therapy - 34th International Austrian Winter Symposium” was granted 14 European CME credits. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

54

6 7

Thursday, 23.1.2020Thursday, 23.1.2020

Mittwoch 22.1.2020

Stellenwert der Lungenszintigraphie aus Sicht des PulmologenO. Burghuber, Wien

10:00 – 10:30

Stellenwert der Lungenszintigraphie aus Sicht des NuklearmedizinersR. Lipp, Graz

10:30 – 11:00

Was sind die Erwartungen der Strahlentherapie an die Nuklearmedizin?F. Sedlmayer, Salzburg

11:00 – 11:30

Strahlentherapieplanung aus Sicht eines Medizinphysikers: Lagerung des Pat, Maske, Atemtriggerung, adaptive Bestrahlung im Laufe der StrahlentherapieU. Wolff, Wien

11:30 – 12:00

Mittagspause 12:00 – 13:00

Rechtsauskunft, Auskunftspflicht, Datenumgang, Befundübermittlung (per FAX, Email...) persönliche Versicherungspflicht für NuklearmedizinerI. Feil, Salzburg

13:00 – 13:30

PRÄ-KONGRESS SYMPOSIUM

Update Nuklearmedizinische Therapie: Status quo und Ausblick – Part 1: RadiojodtherapieC. Pirich, Salzburg

13:30 – 14:00

Update Nuklearmedizinische Therapie: Status quo und Ausblick – Part 2: Beyond RadiojodtherapieA. Haug, Wien

14:00 – 14:30

Kaffeepause 14:30 – 15:00

Nuklearmedizinische Fragestunde:

Beyond FDG PET/CT (SST, PSMA, Cholin, DOPA, FLT, FET, Amyloid)C. Uprimny, InnsbruckA. Kurtaran, WienS. Mirzaei, WienA. Becherer, Feldkirch

15:00 – 16:30

8 9


WEDNESDAY, 22.1.2020

Opening Ceremony

Welcome Words O. Israel – Congress Chair M. Hacker – President OGNMB

The Zell Lecture - Medical Economics in Nuclear Medicine: Chances & ChallengesR. Zimmermann, Lalaye

19:00 – 20:30

Welcome Reception 20:30 – 22:00

SCIENTIFIC PROGRAMME

10 11


THURSDAY 23.1.2020

Lunch Break 12:30 – 14:00Industry Lunch Symposium (more details on page 30)

Session 3 – Alternative Views on Radionuclide TherapyChairs: B. Gruy, Linz & H. Ahmadzadehfar, Bonn

Clinical Dosimetry and its impact on daily practice - interactive session with TEDW. Jentzen, EssenL. Freudenberg, Essen

Toxic SE of radionuclide therapyH. Ahmadzadehfar, Bonn

14:00 – 15:30

Coffee Break 15:30 – 16:00

Session 1 – The Brain as StarterChairs: T. Traub-Weidinger, Vienna & P. Meyer, Freiburg

The clinical need for molecular imaging in Neurology T. Berger, Vienna

The Nuclear Medicine view on Parkinson syndromes P. Meyer, Freiburg

Nuclear Medicine in differential diagnosis of dementiaP. Bartenstein, Munich

09:00 – 10:30


Session 2 – The Scientific Chair Session The many faces of MSK hybrid imagingChairs: O. Israel, Haifa & M. Hacker, Vienna

IntroductionO. Israel, Haifa

The bone in cancer: more than a nice pictureZ. Keidar, Haifa

Benign condition: a zebra or a horse?P.A. Erba, Pisa

11:00 – 12:30

12 13


Session 4 Chairs: M. Mitterhauser, Vienna & I. Virgolini, Innsbruck

211At-labelled poly-L-lysine based effector molecules for pretargeting applicationsSture Lindegren, Sweden

The influence of the application of furosemide combined with hydration on the occurence of halo artifact and on the intensity of tracer accumulation in the urinary bladder in [68Ga]Ga-PSMA-11 PET/CTSteffen Bayerschmidt, Austria

Comparison of two attenuation correction methods for semi-quantitative lymphoscintigraphy of the lower extremitiesAnna Zifko, Austria

[18F]FET and [18F]fluoro-choline PET/CT in primary diagnosis of low grade gliomaAnja Tea Golubić, Croatia

Multimodal in ovo imaging for PET-tracer development: a feasibility studyTheresa Balber, Austria

Synthesis of [68Ga]Ga-DOTA-NOC: First experiences with the simultaneous automated use of two Galli Ad GeneratorsElisabeth Plhak, Austria

16:00 – 17:00


Session 5 – Fireside Conference – Future of Nuclear MedicineModerator: T. Beyer, Vienna & A. Becherer, Feldkirch, M. Gotthardt, Nijmegen

S. Mirzaei, ViennaP. Bartenstein, MunichA. Leisser, ViennaW. Schima, Vienna

17:30 – 18:30

THURSDAY 23.1.2020

14 15


FRIDAY 24.1.2020

Session 6 – Nuclear Medicine in Breast Cancer ImagingChairs: C. Uprimny, Innsbruck & C. Xavier, Brussels

Imaging modalities in breast cancer: What do guidelines recommend?D. Egle, Innsbruck

The role of [18F]FDG-PET/CT in the diagnostic work-up of breast cancer patientsC. Uprimny, Innsbruck

Comparison of [18F]FDG-PET, [18F]NaF-PET and conventional bone scintigraphy in the evaluation of bone metastases in breast cancerM. Beheshti, Aachen

Molecular imaging of breast cancer, PET-tracers beyond [18F]FDG and [18F]NaFM. Keyaerts, Brussels

09:00 – 10:30


Session 7 – Distinguished Pioneer LectureChairs: T. Beyer, Vienna & C. Decristoforo, Innsbruck

Beyond PET/MR: Multiparametric data integration in preclinical and translational researchB. Pichler, Tuebingen

11:00 – 11:30

Session 8 - Radiopharmaceutical aspects in the development of radio-immuno-targetingChairs: T. Beyer, Vienna & C. Decristoforo, Innsbruck

Radionuclide imaging of PD-L1 expression: from radiochemistry to clinical applicationS. Heskamp, Nijmegen

Radiolabeled anti-HER2 nanobody: a theranostic toolC. Xavier, Brussels

11:30 – 12:30

Lunch Break 12:30 – 14:00Industry Lunch Symposium (more details on page 30)

Session 9 - A Pick of Rocket Science in Nuclear Medicine Chairs: A. Haug, Vienna & S. Heskamp, Nijmegen

Deep learningL. Papp, Vienna

Beta cell imaging & bimodal tracersM. Gotthardt, Nijmegen

14:00 – 15:30


16 17


Session 10 – Guided Poster Tour Chairs: E. Guggenberg, Innsbruck & M. Beheshti, Aachen

Improved dosimetry for optimizing intraperitoneal targeted alpha therapy with 211AtStig Palm, Sweden

Feasibility of ultra low-dose thallium stress-redistribution protocol including stress prone imaging in obese patients using a CZT cameraMilan Kaminek, Czech Republic

Technical and economical evaluation of feasibility for implementing small cyclotron systems in Europe for cardiac pet with the tracer [13N]NH3.Klaas Pieter Koopmans, Netherlands

Modification of 68Ga-labelled siderophores for hybride imaging and theranosticsJoachim Pfister, Austria

Case report of a metastatic pheochromocytomaLisa-Maria Rossetti, Austria

Detection of cardiac transthyretin-related amyloidosis (ATTR) with bone scintigraphyAlexander Stephan Kroiss, Austria

Lenvatinib enhanced radioiodine uptake in a patient with low differentiated follicular thyroid cancer with distant metastases: a clinical case reportChristina Tugendsam, Austria

16:00 – 17:00 Serum calcitonin negative medullary thyroid carcinoma : a case ReportBrigitta Schmoll-Hauer, Austria

OGNMB General Assembly 17:00 – 18:30

FRIDAY 24.1.2020

18 19


SATURDAY 25.1.2020

Breakfast Session by Industry 09:00 – 10:30(more details on page 30)

Session 11 – Medullary Thyoid Cancer- an Update (Joint Session OGNMB & OSDG)Chairs: S. Mirzaei, Vienna & R. Prommegger, Innsbruck

Pathological features of MTCO. Koperek, Vienna

Surgery of MTCC. Scheuba, Vienna

Peptide-based targeting strategies for diagnosis and therapy of MTCE. Guggenberg, Innsbruck

09:00 – 10:30


Session 12 – Evergreen Nuclear CardiologyChairs: W. Schaefer, Moenchengladbach & M. Hacker, Vienna

Quantification of perfusion and function from MPS - state of the art 2020W. Schaefer, Moenchengladbach

Imaging infectious endocarditis and CIED infections: where we standP.A. Erba, Pisa

New opportunities in cardiac amyloidosis imaging and therapy: role of Nuclear MedicineR. Slart, Groningen

11:00 – 12:30

ClosingA. Becherer – Congress Chair OGNMBM. Hacker – President OGNMB

12:30 – 13:00

Farewell 13:00 – 14:00

20 21


FREITAG 24. JÄNNER 2020

Begrüßung und offizielle Eröffnung 08:45 – 09:00

Session 1: PETVorsitz: A. Stegmayr, Innsbruck

Radioaktiv markierte Peptide zur Rezeptor-vermittelten Diagnostik und Therapie in der OnkologieE. Guggenberg, Innsbruck

09:00 – 09:30

Standards, Limitationen und Perspektiven der molekularen Bildgebung in der biologisch adaptiven PräzisionsstrahlentherapieM.Zeilinger, Wien

09:45 - 10:30

Pause 10:30 – 11:00Session 2: konv. NUK I Vorsitz: K. Artner, Wien

Somatostatinrezeptorszitigraphie im Rahmen der NET-TumoreCh. Farhan, Wien

11:00 - 11:45

Aufbau & Funktionsweise der D-Spect N. Irnstorfer, Wien

11:45 - 12:30

Mittagspause 12:30 – 14:00

Generalversammlung MTZV der OGNMB 14:00 – 14:30

Session 3: konv. NUK IIVorsitz: A. Gabriel-Werkl, Villach

J131-SD-ThearpieK. Artner, Wien

14:30 - 15:30

Pause 15:30 – 16:00Kritischer Umgang mit Gesundheits-AppsM. Kuprian, Innsbruck

16:00 – 17:00

RADIOLOGIETECHNOLOGIE-SYMPOSIUM 2020

Medizinisch-Technischer Zweigverein der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare BildgebungZVR-Zahl: 513998998, Präsident: Stegmayr Armin, MHPE, T +43 512 5322 76772, [email protected], www.nukmtd.at

Termin: 24.-25. Jänner 2020, Ort: Zell am See (Ferry Porsche Kongresszentrum)Organisation: K. Artner, Wien; A. Gabriel-Werkl, Villach;

22 23


SAMSTAG 25. JÄNNER 2020

Session 4: Forschung/Bacc.-arbeiten Vorsitz: Ch. Harris-Castellitz, WienPoster-Walk 09:00 - 09:30

Poster-Präsentationen 09:30 - 10:00

,,Ist Forschung ArztInnensache?”L. Hehenwarter, Salzburg

10:00 - 10:30

Pause 10:30 – 11:00Session 5: konv. Nuk III Vorsitz: U. Ofner, Graz

Der Einfluss der Akquisitionsparameter auf die Bildqualität einer 123I-FP-CIT SPECT M. Wochinz, Innsbruck

11:00 - 11:30

Eine neue Methode der Knochendichtemessung A.F. Hinterleitner, Steyr

11:30 - 12:00

Preisverleihung THP-Preis, DSD-Poster-Preis und Schlusswort

12:00 – 12:30

Farewell (Hauptkongress) 12:30 – 14:00

Mit der freundlichen Unterstützung folgender Firmen SPONSOREN des ZweigvereinsRADIOLOGIETECHNOLOGIE-SYMPOSIUM 2020

24

Thursday, 23.1.2020

BSM 6 x 3

Seibers-dorf 2 x 2

AAA 3,5 x 2

DSD 2,5 x 2

CATERING

CATERING

Elim

pex

2 x 2

Mediso

3 x 2

MiE GmbH 3 x 2

THP 6 x 3

Sanofi 4 x 2

TopMed Axeleris

2 x 2

IASON 3 x 2

Hermes 3 x 2

ABX 2 x 2

ITM 2 x 2

EISAI 2 x 2

RADIONUCLIDES IN MOLECULAR IMAGING AND THERAPY

34th International Austrian Winter Symposium

January 22-25, 2020

Merck 3 x 2

GE 3 x 2

Norg

ine

2 x 2

Sc

into

mics

– att

2

x 2

SIEMENS

5 x 3

Elysia Raytest

IBA 2 x 2

Pejcl Medizin- technik

RQS

2 x 2

CONGRESS CENTRE

.www.itm.ag

PRECISELY FOR ME.

Dedicated to giving cancer patients better answers than “maybe”.

190524_ITM_Az_210x297_RZ.indd 2 24.05.19 17:16

r

SOMAKIT TOC®

SPOT WHAT OTHERS MAY FAIL TO SEE

28 29

Thursday, 23.1.2020Thursday, 23.1.2020EXHIBITORS

ABX GmbH

ELYSIA RAYTEST

Hermes Medical Solutions

IASON GmbH

Gerhard Pejcl Medizintechnik GmbH

MiE GmbH

AAA – Advanced Accelerator Applications Germany GmbH - a Novartis Company

Axeleris Pharma GmbH

BSM Diagnostica

DSD Pharma GmbH

Eisai GesmbH

Norgine Pharma GmbH

RQS (Ruffani Quality Solutions)

sanofi-aventis GmbH

SCANNWORK medical imaging GmbH

Scintomics/ ATT GmbH

Siemens Healthineers

THP Medical Products Vertriebs GmbH

Seibersdorf Labor GmbH

TopMed Trade E.U.

GE Healthcare Handels GmbH

Elimpex

IBA

ITM Isotopen Technologien München AG

Mediso GmbH

Merck GmbHAXELERIS Pharma GmbH

30 31

Thursday, 23.1.2020Thursday, 23.1.2020CORPORATE MEMBERSINFORMATION LUNCH SYMPOSIUM INDUSTRY

THURSDAY 23. JANUARY 2020

Lunch Symposium by Norgine Targeted identification of Sentinel Lymph Nodes - Lymphoseek in theory and practiceM. HamböckM. Pau

12:30 – 13:30

FRIDAY 24. JANUARY 2020

Lunch Symposium by Advanced Accelerator Applications Germany GmbH

12:30 – 13:30

Beyond NETTER-1 – the evolving role of PRRT in the treatment of NET patientsR. Srirajaskanthan, London

SATURDAY 25. JANUARY 2020

Special Thyroidal Breakfast Session by DSD PharmaOptimizing Thyroxine Treatment: The Role of Softgel PreparationM. Centanni, Rom

08:30 – 09:00

Expanding precision medicine.

The healthcare market operates in a constant state of flux, which can be challenging as you strive for better clinical outcomes, faster work-flow, and consistent quality of results. What if you were able to visualize smaller lesions, get information for more accurate staging and patient risk stratification, and manage opera-tional inefficiencies to facilitate the most appro-priate treatment strategy1?

Accuracy to reveal the bigger picture. Performance to maximize efficiency.

Reproducibility to understand disease progression.

Learn more about Biograph Vision atsiemens.com/vision

1 Based on internal measurements (resolution and time of flight) compared to current systems. Data on file. Biograph Vision is not commercially available in all countries. Its future availability cannot be guaran-teed. Please contact your local Siemens Healthineers organization for further details.

Biograph Vision

See a whole new world of precision

Data

cou

rtes

y of

Cen

tre

Hosp

italie

r Uni

vers

itaire

Va

udoi

s, L

ausa

nne,

Sw

itzer

land

A91

MI-1

0477

-A2-

7600

3.2 mm LSO crystals1

Fast time of flight at 214 ps1

High effective sensitivity at 100 cps/kBq1

100% sensor coverage1

SIE-AUS-19-689_AZ_Biograph_Vision_A5_RZ.indd 1 04.12.19 14:48

RADIONUCLIDES IN MOLECULAR IMAGING & THERAPY FINAL PROGRAMME · of Medicine, Radiopharmacy, Physics...

Documents

Transcript of RADIONUCLIDES IN MOLECULAR IMAGING & THERAPY FINAL PROGRAMME · of Medicine, Radiopharmacy, Physics...